Furthermore, in the context of an emerging protective role of sodium-glucose cotransporter-2 inhibitors (SGLT2-I) and glucagon-like peptide-1 receptor agonists (GLP-1RAs), the therapeutic approaches targeting the management of SIH need to be investigated, thereby reducing hyperglycemia and improving the prognosis. The gene discussed is GLP1R; the disease is Hyperglycemia.